BlinkLab expands autism diagnostic platform through SHANK2 partnership. The ASX-listed autism diagnostic specialist has partnered with the US-based SHANK2 foundation to advance its smartphone-based diagnostic technology. The collaboration focuses on research infrastructure development, data collection, and phenotyping studies for SHANK2-related neurodevelopmental disorders. BlinkLab's platform leverages artificial intelligence and machine learning to provide objective, reflex-based autism diagnostic measures for clinicians. The partnership grants access to genetically confirmed patient populations, strengthening validation of the company's digital biomarker technology. CEO Dr Henk-Jan Boele highlighted that genetically defined conditions provide well-characterized patient groups essential for digital phenotyping development.
Post from MarketNews_en
Log in to interact with content.